Fermion Oy Fermion Oy

X

Find the latest Drugs in Development and Pipeline Prospector News of Delpor.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Delpor
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
150 North Hill Drive, Suite 25 Brisbane, CA 94005
Telephone
Telephone
(415) 480-6870
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.


Lead Product(s): Risperidone

Therapeutic Area: Psychiatry/Psychology Product Name: DLP-114

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.


Lead Product(s): Naltrexone

Therapeutic Area: Psychiatry/Psychology Product Name: DLP-160

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.


Lead Product(s): Tizanidine HCl

Therapeutic Area: Musculoskeletal Product Name: DLP-208

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $2.5 million Upfront Cash: Undisclosed

Deal Type: Funding November 16, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY